The effect of tiotropium on exacerbations and airflow in patients with COPD

The European Respiratory Journal
D DusserP Iacono

Abstract

This randomised, double-blind, parallel-group, 1-yr study compared the effect of tiotropium 18 microg once daily (n=500) and placebo (n=510) on exacerbations, associated health resource use (HRU) and airflow limitation in chronic obstructive pulmonary disease (COPD) patients. The mean+/-sd number of exacerbations during the past year was 2.14+/-1.40, the mean weekly morning peak expiratory flow (PEF) was 259.6+/-96.1 L.min-1 and the mean forced expiratory volume in one second (FEV1) was 1.37+/-0.45 L. Tiotropium significantly delayed the time to first exacerbation by approximately 100 days, reduced the proportion of patients experiencing more than one exacerbation by 17%, and decreased the number of exacerbations by 35% and exacerbation days by 37% versus placebo. Tiotropium also decreased HRU versus placebo, as indicated by the significant reductions in the use of concomitant respiratory medications, antibiotics and oral steroids, and the number of unscheduled physician contacts. Mean weekly morning PEF improved significantly with tiotropium versus placebo from week 1 until the end of the study. At the end of the study, tiotropium significantly improved trough (pre-dose) FEV1, forced vital capacity, slow vital capacity and ins...Continue Reading

Citations

Apr 13, 2013·Drugs & Aging·Timothy E AlbertsonAndrew L Chan
Dec 19, 2009·Current Opinion in Pulmonary Medicine·Donald P Tashkin
Apr 9, 2008·American Journal of Respiratory and Critical Care Medicine·William MacNee
May 9, 2012·American Journal of Respiratory and Critical Care Medicine·M Bradley DrummondRobert A Wise
Jul 28, 2012·The European Respiratory Journal·Jadwiga A WedzichaTerence A R Seemungal
Mar 1, 2011·Respiratory Research·Gabriela VaccaAdrian Gillissen
Apr 27, 2011·Respiratory Research·Paul W JonesEsther Garcia Gil
Oct 8, 2013·Respiratory Research·Shannon CopePaul Jones
Nov 30, 2007·International Journal of Chronic Obstructive Pulmonary Disease·Jane E Scullion
Dec 31, 2010·International Journal of Chronic Obstructive Pulmonary Disease·Martine HoogendoornMaureen Rutten-van Mölken
Feb 12, 2011·International Journal of Chronic Obstructive Pulmonary Disease·James F Donohue, Paul W Jones
Aug 17, 2011·International Journal of Chronic Obstructive Pulmonary Disease·Christopher B CooperSteven Kesten
Oct 18, 2011·International Journal of Chronic Obstructive Pulmonary Disease·Eugene R BleeckerBenjamin Kramer
Jun 12, 2009·International Journal of Chronic Obstructive Pulmonary Disease·Marc Miravitlles, Antonio Anzueto
May 14, 2009·International Journal of Chronic Obstructive Pulmonary Disease·Kai-Michael BeehClaus Vogelmeier
Aug 7, 2009·International Journal of Chronic Obstructive Pulmonary Disease·A AnzuetoS Kesten
Apr 7, 2010·International Journal of Chronic Obstructive Pulmonary Disease·Donald P Tashkin
Aug 18, 2010·International Journal of Chronic Obstructive Pulmonary Disease·Eric BatemanRick Hodder
Nov 29, 2013·Drug Design, Development and Therapy·Annette J TheronRonald Anderson
Aug 31, 2010·PharmacoEconomics·Douglas W MapelJeno P Marton
Mar 26, 2013·Journal of Aerosol Medicine and Pulmonary Drug Delivery·Alexandros G MathioudakisGeorgios A Mathioudakis
May 7, 2014·European Journal of Pharmacology·Angela Marina MontalbanoMirella Profita
Dec 29, 2009·International Journal of Chronic Obstructive Pulmonary Disease·Steven KestenDonald Tashkin
Mar 7, 2014·International Journal of Chronic Obstructive Pulmonary Disease·Nicholas G Csikesz, Eric J Gartman
Oct 13, 2009·Postgraduate Medicine·Antonio R Anzueto
Jun 26, 2015·Expert Review of Clinical Pharmacology·Andrea S Melani
Feb 9, 2008·COPD·Mark T Dransfield, William C Bailey
Apr 23, 2011·The American Journal of the Medical Sciences·Stuart W Stoloff
Jul 14, 2010·The American Journal of the Medical Sciences·Antonio Anzueto
Nov 9, 2007·Chest·Kesavaperumal Vijayasaratha, Robert A Stockley
Oct 3, 2012·Respiratory Physiology & Neurobiology·Marc DecramerGlenn Crater
May 13, 2015·Biometrical Journal. Biometrische Zeitschrift·Christian RöverTim Friede
Jun 30, 2012·Revue des maladies respiratoires·N RocheUNKNOWN groupe d’expert « Exacerbations de BPCO »
Feb 9, 2012·Lancet·Marc DecramerMarc Miravitlles
Apr 26, 2016·Respiratory Medicine·David M G HalpinAntonio Anzueto
Aug 12, 2009·Translational Research : the Journal of Laboratory and Clinical Medicine·Min J JooTodd A Lee
Nov 22, 2008·Pulmonary Pharmacology & Therapeutics·Alaina J AmmitSuzanne Zuyderduyn
Oct 3, 2008·La Presse médicale·Daniel Dusser

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.